BR112016029558A2 - terapia de células-tronco em patologias endometriais - Google Patents

terapia de células-tronco em patologias endometriais

Info

Publication number
BR112016029558A2
BR112016029558A2 BR112016029558A BR112016029558A BR112016029558A2 BR 112016029558 A2 BR112016029558 A2 BR 112016029558A2 BR 112016029558 A BR112016029558 A BR 112016029558A BR 112016029558 A BR112016029558 A BR 112016029558A BR 112016029558 A2 BR112016029558 A2 BR 112016029558A2
Authority
BR
Brazil
Prior art keywords
endometrial
stem cell
cell therapy
regeneration
bmdsc
Prior art date
Application number
BR112016029558A
Other languages
English (en)
Portuguese (pt)
Inventor
Pellicer Antonio
SIMÓN Carlos
Cervello Irene
SANTAMARIA Javier
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of BR112016029558A2 publication Critical patent/BR112016029558A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
BR112016029558A 2014-06-17 2015-06-05 terapia de células-tronco em patologias endometriais BR112016029558A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17
PCT/IB2015/001715 WO2015193737A1 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies

Publications (1)

Publication Number Publication Date
BR112016029558A2 true BR112016029558A2 (pt) 2017-08-22

Family

ID=54329860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029558A BR112016029558A2 (pt) 2014-06-17 2015-06-05 terapia de células-tronco em patologias endometriais

Country Status (22)

Country Link
US (1) US11129851B2 (enExample)
EP (3) EP3158057B1 (enExample)
JP (2) JP6920062B2 (enExample)
CN (2) CN107073040A (enExample)
AU (1) AU2015275798B2 (enExample)
BR (1) BR112016029558A2 (enExample)
CA (1) CA2952559C (enExample)
CY (2) CY1122615T1 (enExample)
DK (2) DK3158057T3 (enExample)
ES (3) ES2983444T3 (enExample)
HR (3) HRP20220419T1 (enExample)
HU (3) HUE044823T2 (enExample)
LT (2) LT3158057T (enExample)
MX (1) MX377300B (enExample)
PL (3) PL4012023T3 (enExample)
PT (2) PT3569697T (enExample)
RS (3) RS65719B1 (enExample)
RU (1) RU2725006C2 (enExample)
SI (2) SI3158057T1 (enExample)
SM (3) SMT201900400T1 (enExample)
TR (1) TR201910410T4 (enExample)
WO (1) WO2015193737A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
EP3272880B1 (en) 2013-03-15 2020-11-25 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
CA2952559C (en) 2014-06-17 2023-01-24 Igenomix S.L. Stem cell therapy in endometrial pathologies
CA3028422A1 (en) * 2016-06-23 2017-12-28 Tithon Biotech, Inc. Cells expressing parathyroid hormone 1 receptor and uses thereof
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
WO2023003130A1 (ko) 2021-07-23 2023-01-26 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700648A (ko) 1989-05-05 1992-08-10 오닐 크리스토퍼 가임성 향상
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
WO2001066786A1 (en) 2000-03-08 2001-09-13 Kliman Harvey J Methods of diagnosing and monitoring endometrial glandular development
AU2001264900A1 (en) 2000-05-24 2001-12-03 Schering Aktiengesellschaft Pharmaceutical use of fibulin-1
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
CA2489568A1 (en) 2002-05-14 2004-07-22 The Board Of Trustees Of The Leland Stanford Junior University Endometrial genes in endometrial disorders
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
AU2003255355A1 (en) 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10361928A1 (de) 2002-12-21 2004-07-01 Universität Leipzig Verfahren und Mittel zur Bestimmung von bestimmten Zuständen bzw. Veränderungen im Uterusepithel und im Epithel anderer Organe
WO2005018796A1 (en) 2003-08-21 2005-03-03 Pamgene B.V. Microarray support for bioprobe synthesis
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
WO2005026324A2 (en) 2003-09-08 2005-03-24 The Board Of Regents Of The University Of Texas System Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog
EP2251695B1 (en) 2003-12-23 2013-07-17 Mount Sinai Hospital Corporation Markers associated with endometrial disease
EP1765083A4 (en) 2004-05-28 2008-08-20 Serono Lab USE OF IL-17 TO TREAT FERTILITY DISORDERS
US20090111140A1 (en) * 2006-03-31 2009-04-30 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2*
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
ES2662571T3 (es) 2011-10-21 2018-04-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos de evaluación de la receptividad endometrial de una paciente tras una hiperestimulación ovárica controlada
CN104053668B (zh) 2011-11-30 2020-09-11 新加坡科技研究局 用于生物学检测的gm1神经节苷脂与膜联蛋白v的微粒多肽比例
ES2681238T3 (es) 2012-06-27 2018-09-12 F. Hoffmann-La Roche Ag Medios y métodos de aplicación de la relación sFlt-1/PIGF o Endoglina/PIGF para descartar la aparición de preeclampsia en un cierto periodo de tiempo
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
BR112016021630A2 (pt) 2014-03-21 2020-02-27 Igenomix, S.L. Composição para tratar pré-eclampsia, método de uso do nível de anexina a2 (anxa2) como indicador de pré-eclampsia e método para avaliar a eficácia da terapia de glicosaminoglicano para pré-eclampsia
CA2952559C (en) 2014-06-17 2023-01-24 Igenomix S.L. Stem cell therapy in endometrial pathologies

Also Published As

Publication number Publication date
ES2736117T3 (es) 2019-12-26
LT3569697T (lt) 2022-04-25
PL3158057T3 (pl) 2020-05-18
EP3569697B8 (en) 2022-04-27
CY1122615T1 (el) 2021-03-12
HRP20220419T1 (hr) 2022-05-27
TR201910410T4 (tr) 2019-08-21
SMT202400270T1 (it) 2024-07-09
JP6920062B2 (ja) 2021-08-18
EP3158057B1 (en) 2019-04-17
RU2017101147A (ru) 2018-07-17
EP4012023B1 (en) 2024-05-15
LT3158057T (lt) 2019-09-25
EP3569697B1 (en) 2022-01-05
DK3569697T3 (da) 2022-04-04
HRP20240798T1 (hr) 2024-09-27
EP4012023C0 (en) 2024-05-15
CA2952559A1 (en) 2015-12-23
EP4012023A1 (en) 2022-06-15
SMT201900400T1 (it) 2019-09-09
PT3569697T (pt) 2022-05-02
JP2017522288A (ja) 2017-08-10
AU2015275798A1 (en) 2017-02-02
MX377300B (es) 2025-03-07
CA2952559C (en) 2023-01-24
HUE067463T2 (hu) 2024-10-28
CN107073040A (zh) 2017-08-18
PT3158057T (pt) 2019-07-19
RS59210B1 (sr) 2019-10-31
RU2725006C2 (ru) 2020-06-29
CN116747241A (zh) 2023-09-15
HUE044823T2 (hu) 2019-11-28
AU2015275798B2 (en) 2021-03-25
JP2020138984A (ja) 2020-09-03
SMT202200155T1 (it) 2022-05-12
PL4012023T3 (pl) 2024-09-02
US11129851B2 (en) 2021-09-28
RS63093B1 (sr) 2022-04-29
HRP20191240T1 (hr) 2019-11-01
ES2910306T3 (es) 2022-05-12
SI3158057T1 (sl) 2019-10-30
SI3569697T1 (sl) 2022-05-31
CY1125938T1 (el) 2024-02-16
HUE058328T2 (hu) 2022-07-28
RU2017101147A3 (enExample) 2019-02-06
RS65719B1 (sr) 2024-08-30
US20170128492A1 (en) 2017-05-11
MX2016016756A (es) 2017-11-02
ES2983444T3 (es) 2024-10-23
DK3158057T3 (da) 2019-07-29
WO2015193737A1 (en) 2015-12-23
PL3569697T3 (pl) 2022-07-04
EP3569697A1 (en) 2019-11-20
EP3158057A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
IL253879A0 (en) Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
BR112017003111A2 (pt) composições e métodos para o tratamento de distúrbios neurológicos
CL2015002640A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
BR112017005630A2 (pt) células t de memória central para terapia adotiva com células t
DK3024498T3 (da) Aav-variant og sammensætninger, fremgangsmåder og anvendelser til genoverførsel til celler, organer og væv
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MA52542A (fr) Thérapie cellulaire adoptive
DK3325025T3 (da) Sammensætning og produkter omfattende aldrende celler til anvendelse i vævsregeneration
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2017004198A (es) Composiciones y equipos para tratar prurito y metodos para utilizar los mismos.
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PT3365432T (pt) Terapêutica com células estaminais baseada em células estaminais derivadas de tecido adiposo
NZ721835A (en) An osseointegrable device
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.